Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Gilead Japan Files Trodelvy for 1st-Line TNBC in PD-1/PD-L1-Ineligible Patients
Gilead Sciences said on February 13 that it has filed in Japan for a label expansion of its TROP2-directed antibody drug conjugate (ADC) Trodelvy (sacituzumab govitecan) for use as a first-line therapy for certain patients with triple-negative breast cancer (TNBC).…
To read the full story
Related Article
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
- Gilead Files Trodelvy for HR+/HER2- Breast Cancer in Japan
April 25, 2025
- Tepezza, Trodelvy, and More Drugs Now Available in Japan; Kisunla Due Out on Nov. 26
November 21, 2024
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
- Toho Confirms Preliminary Bid for PHC as It Mulls Buyout
October 2, 2026
- Gilead Paints Sustained Growth Curve with Trodelvy, CAR-T Therapies
October 2, 2026
- Novo Expands Oral Obesity Arsenal, Hengrui Asset Eyed around 2030
October 1, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…